|The full article is available to subscribers||Subscriber Login|
The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess), another guanylate cyclase-C receptor agonist, and lubiprostone (Amitiza), a chloride channel activator, were approved earlier for treatment of CIC in adults.1
CHRONIC IDIOPATHIC CONSTIPATION — Symptoms of CIC include infrequent bowel movements (typically <3 defecations per week), straining when defecating, lumpy or hard stools, a sensation of anal blockage or incomplete evacuation, and a need for manual maneuvers to aid defecation.2
Dietary changes (increased fiber and water intake) and bulk-forming laxatives are usually tried first. When these fail, osmotic laxatives such as polyethylene glycol and stimulant laxatives such... more
- Drugs for irritable bowel syndrome. Med Lett Drugs Ther 2016; 58:121.
- EM Quigley and L Neshatian. Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother 2016; 17:501.
- AC Ford et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 2014; 109 Suppl 1: S2.
- A Wald. Constipation: advances in diagnosis and treatment. JAMA 2016; 315:185.
- PB Miner Jr et al. A randomized phase III clinical trial of plecanatide, a uroguanylin analog, in patients with chronic idiopathic constipation. Am J Gastroenterol 2017; 112:613.
- PB Miner et al. Efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation (CIC): results from a multicenter phase III study (study-03). Gastroenterology 2016; 150:S497. Abstract Su1214.